COVID-19 pill developers aim to top Merck, Pfizer efforts
As Merck and Pfizer prepare to report clinical trial results for experimental COVID-19 antiviral pills, rivals are lining up with what they hope will prove to be more potent and convenient oral treatments of their own. Enanta Pharmaceuticals, Pardes Biosciences, Japan’s Shionogi and Novartis said they have designed antivirals that specifically target the coronavirus while […]
Posted from: this blog via Microsoft Flow.
Comments
Post a Comment